Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus H R 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus H R 50.
DELATESTRYL vs H.R.-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
50 to 200 mg intramuscularly every 2 to 4 weeks.
12.5 mg orally twice daily
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Category C
Category C
Androgen
Androgen